Compare Inovio Pharmaceuticals Inc (INO) vs Rush Street Interactive Inc (RSI) Price & Performance

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Rush Street Interactive (RSI) trades at $24.28, down 1.78% over 24 hours, with a bearish technical signal from moving averages despite bullish oscillators. The company reported record Q2 2026 revenue of $393.8 million, up 46% year-over-year, and raised full-year guidance. Financials show strong revenue growth but thin net margins of 2.33%, with elevated valuation ratios like a P/E of 81.13. Analyst consensus is strongly bullish with a $34.75 price target.

The outlook is positive due to robust revenue growth and expansion in online casino and sports betting markets, but risks include high valuation sensitivity and competitive pressures. Institutional buying by firms like Dimensional Fund Advisors supports sentiment, though insider selling post-rally warrants monitoring. The stock offers growth potential if execution continues, but investors should weigh margin pressures against expansion prospects.